Precision Genomic Medicine: How Close Are We?

NYC Health Business Leaders > Precision Genomic Medicine: How Close Are We?
 

Sponsors & Hosts

Memorial Sloan-Kettering Cancer Center

Much has been made of the promise of genome sequencing in creating new frontiers in the treatment of diseases ranging from cancer to schizophrenia. As the cost to sequence the human genome has fallen from $2 billion to only a few thousand dollars in about a decade, it appears that we are on the verge of a revolution in healthcare.

And as the home to a number of major academic medical centers and research institutions, in addition to the forthcoming NY Genome Center, New York City is at the center of this leap forward in medicine. Consequently, we have assembled a panel of leaders in the field who will describe the promise, the practice and the challenges of what is being called precision medicine. Ken Offit, MD is Chief of the Clinical Genetics Service at Memorial Sloan-Kettering Cancer Center; Robert Darnell, MD, PhD is the President & Scientific Director of the New York Genome Center; and Wendy Chung, MD, PhD directs the clinical genetics program at Columbia University. Together they will offer insights from the front line of a continually evolving field that will likely affect how all of us receive care in the not-too-distant future.

Speakers

MICHAEL BERGER, PHD

Research Scientist in Cancer Genetics
Memorial Sloan-Kettering Cancer Center
read bio

WENDY CHUNG, MD, PHD

Director, Clinical Genetics
NY-Presbyterian/Columbia University Medical Center
read bio

ROBERT DARNELL, MD, PHD

President and Scientific Director
New York Genome Center
read bio

KENNETH OFFIT, MD

Chief of the Clinical Genetics Service
Memorial Sloan-Kettering Cancer Center
read bio